YR0101
Human PD-1 Monoclonal Antibody
Size
£486.00
- SKU:
- YR0101
- Additional Names:
- CD279|hPD-1|hPD-l|hSLE1|PD1|PDCD1|SLEB2
- Application:
- ELISA, FuncS, Neutralisation
- Molecular Weight:
- 150 kDa
- Purity:
- >95%
- Storage Conditions:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Supplier:
- Abclonal
- Immunogen:
- Human PD-1
- Formulation:
- Purified from cell culture supernatant in an animal-free facility
- Uniprot:
- Q15116
- Synonyms:
- CD279;hPD-1;hPD-l;hSLE1;PD-1;PD1;programmed cell death 1 protein;programmed cell death protein 1;protein PD-1;SLEB2;systemic lupus erythematosus susceptibility 2
- Extra Details:
- Spartalizumab Biosimilar uses the same protein sequences as the therapeutic antibody spartalizumab. A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.
- Shipping Conditions:
- Blue Ice